ARCUS BIOSCIENCES INC (RCUS) Stock News

NYSE:RCUS - New York Stock Exchange, Inc. - US03969F1093 - Common Stock - Currency: USD

8.94 -0.18 (-1.97%)

After market: 8.94 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

RCUS Latest News, Press Relases and Analysis

All

Press Releases

15 hours ago - Benzinga

What to Expect from Arcus Biosciences's Earnings

11 days ago - Arcus Biosciences

Arcus Biosciences Announces New Employment Inducement Grants

12 days ago - Arcus Biosciences

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

13 days ago - Benzinga

Forecasting The Future: 5 Analyst Projections For Arcus Biosciences

13 days ago - Arcus Biosciences

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

a month ago - Arcus Biosciences

Arcus Biosciences Announces New Employment Inducement Grants

a month ago - Arcus Biosciences

Arcus Biosciences Announces New Employment Inducement Grants

2 months ago - Arcus Biosciences

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

2 months ago - Arcus Biosciences

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

2 months ago - Arcus Biosciences

Arcus Biosciences Announces New Employment Inducement Grants

3 months ago - Arcus Biosciences

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

3 months ago - Arcus Biosciences

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

3 months ago - Arcus Biosciences

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

3 months ago - Arcus Biosciences

Arcus Biosciences Announces New Employment Inducement Grants

3 months ago - Arcus Biosciences

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

3 months ago - Arcus Biosciences

Arcus Biosciences Announces New Employment Inducement Grants

3 months ago - Arcus Biosciences

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

4 months ago - Arcus Biosciences

Arcus Biosciences Announces New Employment Inducement Grants

5 months ago - Arcus Biosciences

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

5 months ago - Arcus Biosciences

Arcus Biosciences Announces New Employment Inducement Grants

5 months ago - Arcus Biosciences

Arcus Biosciences Announces New Employment Inducement Grants

6 months ago - Arcus Biosciences

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

6 months ago - Arcus Biosciences

Arcus Biosciences Announces New Employment Inducement Grants

6 months ago - Arcus Biosciences

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

6 months ago - Arcus Biosciences

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer